Depth of Anesthesia 8: Does ketorolac increase the risk of bleeding?
Sep 20, 2019
Jamie Sparling, anesthesiologist and recent MGH Critical Care fellow now on faculty, tackles whether ketorolac raises surgical bleeding risk. He reviews landmark studies, volunteer bleeding-time data, randomized trials, and meta-analyses. Short, evidence-focused segments compare overall clinical bleeding rates versus specific concerns like adult tonsillectomy.
AI Snips
Chapters
Books
Transcript
Episode notes
Break Down The Core Claims
- The main claim is that ketorolac increases bleeding and should be avoided when operative blood loss is a concern.
- Subclaims include platelet inhibition, translation to surgical bleeding, clinical relevance, and risk-benefit balance.
FDA Black Box Is Based On Postmarketing Reports
- The FDA black box warns perioperative ketorolac should be avoided because post-marketing reports linked it to operative hematomas and wound bleeding.
- The label advises caution when hemostasis is critical based on reported post-marketing experience.
Large Cohort Showed GI But Not Operative Bleeding
- The 1996 Straum JAMA cohort (≈10,000 pts) found no significant increase in operative-site bleeding with parenteral ketorolac.
- It did find a significant increase in GI bleeding, especially in older patients.
